Candel Therapeutics (CADL) Cash & Equivalents: 2020-2023
Historic Cash & Equivalents for Candel Therapeutics (CADL) over the last 3 years, with Sep 2023 value amounting to $43.0 million.
- Candel Therapeutics' Cash & Equivalents fell 44.29% to $43.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $43.0 million, marking a year-over-year decrease of 44.29%. This contributed to the annual value of $70.1 million for FY2022, which is 15.23% down from last year.
- As of Q3 2023, Candel Therapeutics' Cash & Equivalents stood at $43.0 million, which was down 17.15% from $51.9 million recorded in Q2 2023.
- Candel Therapeutics' 5-year Cash & Equivalents high stood at $94.3 million for Q1 2022, and its period low was $24.3 million during Q2 2021.
- In the last 3 years, Candel Therapeutics' Cash & Equivalents had a median value of $73.6 million in 2022 and averaged $67.8 million.
- In the last 5 years, Candel Therapeutics' Cash & Equivalents spiked by 256.89% in 2022 and then crashed by 44.29% in 2023.
- Over the past 4 years, Candel Therapeutics' Cash & Equivalents (Quarterly) stood at $35.1 million in 2020, then surged by 135.76% to $82.6 million in 2021, then dropped by 15.23% to $70.1 million in 2022, then crashed by 44.29% to $43.0 million in 2023.
- Its Cash & Equivalents stands at $43.0 million for Q3 2023, versus $51.9 million for Q2 2023 and $59.3 million for Q1 2023.